I
Ivana Sestak
Researcher at Queen Mary University of London
Publications - 132
Citations - 8732
Ivana Sestak is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 34, co-authored 124 publications receiving 7449 citations. Previous affiliations of Ivana Sestak include The Royal Marsden NHS Foundation Trust & Cancer Research UK.
Papers
More filters
Journal ArticleDOI
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick,Ivana Sestak,Michael Baum,Aman U. Buzdar,Anthony Howell,Mitch Dowsett,John F. Forbes +6 more
TL;DR: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial as discussed by the authors was designed to compare the efficacy and safety of anastrozole (1 mg) with tamioxifen (20 mg) as adjuvant treatment for postmenopausal women with early stage breast cancer.
Journal ArticleDOI
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Mitch Dowsett,Ivana Sestak,Elena Lopez-Knowles,Kalvinder Sidhu,Anita K. Dunbier,J. Wayne Cowens,Sean Ferree,James Storhoff,Carl Schaper,Jack Cuzick +9 more
TL;DR: ROR provides more prognostic information in endocrine-treated patients with ER-positive, node-negative disease than RS, with better differentiation of intermediate- and higher-risk groups.
Journal ArticleDOI
Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer—96-Month Follow-up of the Randomized IBIS-I Trial
TL;DR: The prophylactic effect of tamoxifen was fairly constant for the entire follow-up period, and no diminution of benefit was observed for up to 10 years after randomization, but side effects in the tamoxIFen group were much lower after completion of the active treatment period than during active treatment.
Journal ArticleDOI
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial
Jack Cuzick,Ivana Sestak,John F. Forbes,Mitch Dowsett,Jill Knox,Simon Cawthorn,Christobel Saunders,Nicola Roche,Robert E. Mansel,Gunter von Minckwitz,Bernardo Bonanni,Tiina Palva,Anthony Howell +12 more
TL;DR: Anastrozole effectively reduces incidence of breast cancer in high-risk postmenopausal women, and the fact that most of the side-effects associated with oestrogen deprivation were not attributable to treatment, provides support for the use of anastroZole in post menopausal women at high risk of Breast cancer.
Journal ArticleDOI
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
Jack Cuzick,Ivana Sestak,Sarah E Pinder,Ian O. Ellis,Sharon Forsyth,Nigel J Bundred,John F. Forbes,H Bishop,Ian S. Fentiman,W.D. George +9 more
TL;DR: This updated analysis confirms the long-term beneficial effect of radiotherapy and reports a benefit for tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision.